Metal Nanocomposites in Nanotherapeutics for Oxidative Stress-Induced Metabolic Disorders

Anindita Behera is an Associate Professor, Department of Pharmaceutical Analysis, Siksha ‘O’ Anusandhan Deemed to be University. She did her masters from Pune University, India, and Ph.D. from Siksha ‘O’ Anusandhan Deemed to be University. She has developed new analytical methods for drug formulations used in the treatment of AIDS. Currently, she is involved in the green synthesis of nanomaterial targeting different life-risk diseases. She has more than 15 years of experience in research and academics. She has published several research and review articles in peer-reviewed journals. She has also contributed many book chapters to books published with other leading publishers. She has guided two Ph.D. scholars; eleven post-graduate scholars and 30 undergraduate students.

Chapter 1. Oxidative stress-induced metabolic disorders: Mechanism and pathogenesis1.1. Introduction
1.2. Metabolic diseases and oxidative stress
1.3. Oxidative stress and metabolic disorder leading to diabetes
1.4. Oxidative stress leading to CVD
1.5. Oxidative stress resulting in carcinogenesis
1.6. Oxidative stress leading to obesity
1.7. Conclusion and Future Prospects
References

Chapter 2. Metal nanocomposites: synthesis, characterization, and biomedical applications
2.1. Introduction
2.2. Historical Background
2.3. Properties of Nanocomposites
2.4. Classification of Nanocomposites
2.5. Emerging trends in the Metal Oxide nanocomposites
2.6. Fabrication of the Metal Oxide Nanocomposites
2.7. Characterization of the fabricated Metal Oxide Nanocomposites
2.8. Factors influencing the fabrication and characterization of Metal Oxide Nanocomposites
2.9. Biomedical applications of the Metal Oxide Nanocomposites in oxidative stress-induced disorders
2.10. Challenges and Limitations of the Metal Oxide Nanocomposites
2.11. Conclusion and Future perspectives
References

Chapter 3. The general concept of metal nanocomposites in nanotherapeutics against oxidative stress-induced metabolic disorders3.1. Nanotherapeutics and Nanocomposites
3.2. Oxidative stress (OS)-induced metabolic disorders (MD)
3.3. Role of metal nanocomposites in theranostic and management of OS-induced metabolic disorders
3.4. Conclusion and future perspectives of MNCs
References

Chapter 4. Nanotherapeutics for leptin resistance and obesity using metal nanocomposites4.1. Introduction
4.2. Pathophysiology of leptin resistance and obesity
4.3. Relation between oxidative stress and Obesity
4.4. Pharmacological Treatment of Obesity and challenges
4.5. Theranostic applications of metal nanocomposites in leptin resistance and obesity
4.6. Conclusion and future perspectives
References

Chapter 5. Nanotherapeutics for insulin resistance and diabetes mellitus using metal nanocomposites
5.1 Diabetes Mellitus (DM) and Insulin Resistance
5.2 Mechanisms of Insulin Resistance and Diabetes caused by Oxidative Stress
5.3 Diagnosis of Diabetes Mellitus
5.4 Metal-based Nanosensors in Diagnosis of Diabetes Mellitus
5.5 Treatment of Diabetes Mellitus and Insulin Resistance
5.6 Conclusion and Future prospectives
References

Chapter 6. Nanotherapeutics for diabetic retinopathy with metal nanocomposites
6.1. Introduction
6.2. Anatomy and Physiology of Retina
6.3. Pathophysiology of Diabetic Retinopathy
6.4. Treatment
6.5. Drawbacks of conventional therapy
6.6. Metal nanocomposites
6.7. Applications of Metal nanocomposites in DR
6.8. Recent advances and future perspectives
6.9. Conclusions
References

Chapter 7. Nanotherapeutics for diabetic nephropathy with metal nanocomposites
7.1. Introduction
7.2. Metal nanocomposites in diabetic nephropathy
7.3. Future perspectives
7.4. Conclusion
References

Chapter 8. Nanotherapeutics for diabetic cardiomyopathy using metal nanocomposites
8.1. Introduction
8.2. Signaling pathways of DCM
8.3. Current therapeutic implications and challenges in DCM
8.4. Nanomaterials as drug therapy for diabetic cardiomyopathy
8.5. Recent trends in the treatment of DCM with nanocomposites
8.6. Challenges, Limitations, and Future Prospectives
8.7. Conclusion
References

Chapter 9. Nanotherapeutics for a diabetic foot ulcer and wound healing with metal nanocomposites

9.1. Diabetic foot ulcer and wound healing
9.2. Design of metal nanocomposites and their applications in wound healing
9.3. Biocompatibility of metal nanocomposites
9.4. Patents on metal nanocomposites for DFU and wound healing
9.5. Current challenges and prospects
9.6. Conclusion
References

Chapter 10. Nanotherapeutics for management of dyslipidemia
10.1. Introduction
10.2. Etiopathogenesis of dyslipidemia
10.3. Management of dyslipidemia
10.4. Plant-based drugs for dyslipidemia
10.5. Nanotherapeutics for dyslipidaemia
10.6. ROS-based nanotherapeutics against dyslipidaemia
10.7. Conclusion
References

Chapter 11. Nanotherapeutics for endometrial cancer with metal nanocomposites
11.1 Introduction
11.2 Molecular mechnism of endometrial cancer
11.3 Recent Difficulties in Endometrial Cancer Treatment
11.4 Future Treatment Approaches in Endometrial Cancer: Metalloproteinase Inhibitors
11.5 Nanomedicines and cancer treatments based on glycans

11.6 Nanocomposites of Polymers and Metals in the Treatment of Endometrial Cancer
11.7 Conclusion
References

Chapter 12. Nanotherapeutics for colorectal cancer using metal nanocomposites
12.1. Introduction
12.2. Cancer Cell Biology: Exploiting Deviant Physiological Features
12.3. Metal/Carbon Nanoparticles in Microbot/Nanobot design
12.4. Synthetic Strategies for Nanocomposites
12.5. Colorectal Cancer Models
12.6. Strategies of Colorectal Cancer Cell/Tumor Targeting
12.7. Conclusions and Path Forward
References

Chapter 13. Nanotherapeutics for ovarian cancer using metal nanocomposites

13.1. Introduction
13.2. Pathogenesis of Ovarian cancer
13.3. Challenges with current therapy for ovarian cancer treatment
13.4. Classification and Applications of metal nanocomposites
13.5. Benefits of metal nanocomposites in treating ovarian cancer
13.6. Challenges in using metal nanocomposites for ovarian cancer
13.7. Adverse effects/toxicities associated with the use of metal nanocomposites
13.8. Conclusion and Future Perspectives
References

Chapter 14. Nanotherapeutics for breast cancer using metal nanocomposites
14.1. Introduction
14.2. Conventional treatment for breast cancer
14.3. Nanotechnology-based approaches to treat breast cancer
14.4. Different nano-formulations for the Therapy of breast cancer
14.5. Metal Nanocomposites for Breast Cancer
14.6. Role of metal nanocomposites in breast cancer treatment
14.7. Conclusion
References

Chapter 15. Nanotherapeutics for liver cancer with metal nanocomposites15.1. Introduction
15.2. Biocompatibility and Toxicity of Nanocomposites
15.3. Nano-antioxidants
15.4. Macromolecular Nanocomposites
15.5. Targeting Nanocomposites to HCC
15.6. Nanocomposites in the Therapy of HCC
15.7. Limitations of Nanocomposites
15.8. Conclusions
Reference

Chapter 16. Nanotherapeutics for reversal against multidrug resistance in chemotherapy with metal nanocomposites
16.1 Introduction
16.2 Nanotherapeutics
16.3 Metal Nanocomposites
16.4 Metal Oxide Nanocomposites:
16.5 Conclusion
References

Chapter 17. Nanotherapeutics for Alzheimer’s disease using metal nanocomposites17.1. Introduction
17.2. Role of Metal nanocomposites in neurodegeneration: From inception to treatment
17.3. Metal nanocomposites utilized in the detection and treatment of Alzheimer's disease
17.4. Conclusion
References

Chapter 18. Nanotherapeutics for PD using metal nanocomposites
18.1. Background
18.2. Pathophysiology of PD
18.3. Current therapeutics for PD
18.4. Nanotherapeutics: A promising approach in the treament of PD

18.5. Applications of metal nanocomposites for PD
18.6. Conclusion
References